|
Patient characteristics |
||
| Characteristics |
ER-negative group (n = 51) |
ER-positive group (n = 82) |
|
|
||
| Age, years |
||
| Median |
51 |
51 |
| Range |
29–75 |
28–79 |
| T stage |
||
| T0 |
0 |
1 (1%) |
| T1 |
8 (16%) |
4 (5%) |
| T2 |
24 (47%) |
46 (56%) |
| T3/4 |
19 (37%) |
31 (38%) |
| Histological grade |
||
| Grade 1 |
0 |
2 (2%) |
| Grade 2 |
6 (12%) |
45 (55%) |
| Grade 3 |
43 (84%) |
31 (38%) |
| Unknown |
2 (4%) |
4 (5%) |
| Lymph node status |
||
| Positive |
38 (75%) |
55 (67%) |
| Negative |
13 (25%) |
27 (33%) |
| HER2 overexpressed or amplified |
||
| Yes |
18 (35%) |
15 (18%) |
| No |
32 (63%) |
67 (82%) |
| Unknown |
1 (2%) |
0 |
| Pathologic complete response |
||
| Yes |
27 (53%) |
7 (9%) |
| No |
24 (47%) |
75 (91%) |
|
ER, estrogen receptor. | ||
Tordai et al. Breast Cancer Research 2008 10:R37 doi:10.1186/bcr2088 |
||